Schering Aktiengesellschaft

Berlex Laboratories, Inc.

Cooper Laboratories, Inc.

Ronald A Wohl

William C Lumma, Jr

Julius Diamond

Thomas K Morgan, Jr

Klaus Nickisch

Randall E Lis

David D Davey

Paul W Erhardt

Alfred A Hagedorn, Iii

Stanley S Greenberg

Novel derivatized alkanolamines of the following structural formula ##STR1## are described as useful cardiovascular agents. Most especially described is their usefulness as cardiovascular agents exhibiting an antiarrhythmic effect. Said antiarrhythmic effect is of a combination Class II/Class III variety. Pharmaceutical formulations containing such compounds are also described.

Derivatized alkanolamines as cardiovascular agents

Novel N-[4-(aminosubstituted)phenyl]methanesulfonamides and their use as cardiovascular agents, especially as antiarrhythmic agents are described. Pharmaceutical formulations containing such compounds are also discussed.

Novel N-[4-(aminosubstituted)phenyl]methanesulfonamides and their use as

Novel 1-(4-substituted phenyl)-1H-imidazoles and their use as antiarrhythmic, anti-hypertensive and anti-ischemic agents is described. Pharmaceutical formulations containing such compounds are also discussed.

1-(4-Substituted phenyl)-1H-imidazoles compounds

Novel substituted 4-[1H-imidazol-1-yl]benzamides and their use in the treatment of cardiac arrthythmias especially as Class III or combination Class I/III antiarrhythmic agents is described. Pharmaceutical formulations containing such compounds are also disclosed.

Substituted 4-(1H-imidazol-1-yl)benzamides as antiarrhythmic agents

Novel imidazolonecarbonylarylimidazoles are described having cardiovascular properties, especially as cardiotonic agents in the treatment of congestive heart failure. Pharmaceutical formulations containing such compounds are also provided. Further, a novel process for the preparation of the compounds and intermediates useful thereto of this invention is disclosed.

Process for the preparation of imidazolonecarbonylarylimidazoles

The imidazolium salts described are useful as antiarrhythmic agents. A method of treating arrhythmia by increasing the refractoriness of cardiac tissue is provided as well as pharmaceutical formulations containing such imidazolium salts.

Antiarrhythmic imidazoles

Novel substituted sulfonamidobenzamides are described as useful antiarrhythmic agents. Their use in the treatment of cardiac arrhythmias, especially re-entrant arrhythmias, via the prolongation of the action potential of cardiac tissue is provided. Pharmaceutical formulations containing such compounds are also disclosed.

Substituted sulfonamidobenzamides and method of treating arrhythmias

Antiarrhythmic imidazoliums

The imidazolium salts described are useful as antiarrhythmic agents. A method of treating arrhythmia by increasing the refractoriness of cardiac tissue is provided as well as pharmaceutical formulations containing such imidazolium salts. The compounds are described by the following formula: ##STR1##

Novel imidazolonecarbonylarylimidazoles of the formula: ##STR1## are described having cardiovascular properties, especially as cardiotonic agents in the treatment of congestive heart failure. Pharmaceutical formulations containing such compounds are also provided. Further, a novel process for the preparation of the compounds and intermediates useful thereto of this invention is disclosed.

Cardiotonic 1,3-dihydro-4-[[(imidazol-1-yl)aryl]carbonyl]imidazol-2-ones

The novel unsaturated arylalkyl ammonium salts described herein are useful as antiarrhythmic agents. A method of treating arrhythmia by increasing the refractoriness of cardiac tissue is provided, as well as pharmaceutical formulations containing such ammonium salts.

Substituted phenylalkenyl ammonium salts as antiarrhythimc agents

Substituted sulfonamidobenzamides, antiarrhythmic agents and

The compound N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-1H-benzimidazole-1-butanamine and methods for its manufacture and use are described herein. The compound is a cardiotonic agent useful primarily in the treatment of congestive heart failure.

N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-1H-benzimidazole-1-butanamine and

3-Phenoxy-2-hydroxypropylamines having an N-benzimidazolyalkyl substituent and similar compounds are described herein. They are obtained by the reaction of the appropriate imidazole-1-alkanamine with an epoxide, and they are useful primarily as .beta..sub.1 -agonists/.beta.-sympathomimetic agents.

Treating cardiovascular diseases with

Novel 1,2-disubstituted imidazol(in)es are described herein. The compounds are generally produced by reacting a haloacylanilide with an excess of 2-substituted-imidazol(in)e. The compounds are antiarrhythmic agents.

Growing community of inventors

Morris Plains, NJ, United States of America

Ronald A Wohl